News

We deliver cutting-edge diagnostic solutions. Here, you will find timely updates and breakthroughs in our efforts to empower healthcare professionals across the globe, in diagnosing and monitoring blood cancers and immune system disorders. 

Results Found:
Onco Tracker Collaboration
Onco Tracker Collaboration
sBCMA test may both monitor and predict outcomes in multiple myeloma and other blood cancers ONCOtracker.
iStopmm Trial Methods Paper Publication
iStopmm Trial Methods Paper Publication
Binding site is pleased to announce that the methods paper for the landmark iStopMM (Iceland Screens, Treats or Prevents Multiple Myeloma) study has now been published.
Mark Stevenson
Mark Stevenson
The Binding Site, a global leader in specialist protein diagnostics, has appointed Mark Stevenson as new non-executive Chairperson.
Thermo Fisher Scientific to Acquire The Binding Site Group
Thermo Fisher Scientific to Acquire The Binding Site Group
Expands Specialty Diagnostics Segment with Industry Leader in Oncology Testing for Detection and Monitoring of Multiple Myeloma.
Thermo Fisher Scientific Announces Extended 510k Clearance of Freelite Assays for Evaluation of MGUS, a Precursor to Multiple Myeloma
Thermo Fisher Scientific Announces Extended 510k Clearance of Freelite Assays for Evaluation of MGUS, a Precursor to Multiple Myeloma
Thermo Fisher Scientific Inc. announces 510k clearance to market its Optilite® Freelite® assays’ claim for the evaluation of monoclonal gammopathy of undetermined significance (MGUS).
Blood Cancer Awareness Month
Blood Cancer Awareness Month
Blood Cancer Awareness Month is taking place in September, and we are thrilled to announce our partnership with the International Myeloma Foundation to shine a spotlight on blood cancer and raise the profile of Multiple Myeloma, the second most common blood cancer.